NewswireToday - /newswire/ -
Philadelphia, PA, United States, 2009/05/14 - ERT, a leading provider of ePRO solutions, centralized ECG and eClinical technology and other services to the biopharmaceutical, medical device, and related industries.
ERT, a leading provider of ePRO solutions, centralized ECG and eClinical technology and other services to the biopharmaceutical, medical device, and related industries, announced today that it will be showcasing its portfolio of products and services on booth # 507 at the 45th Annual DIA Meeting, 22-25 June 2009 in San Diego, California, USA.
ERT will be showcasing, for the first time since its successful company rebranding exercise, its four new sub-brands of its industry-leading products and services, including ERT ePRO Solutions, ERT Cardiac Safety Solutions, ERT EDC Solutions and ERT Clinical Research Consulting Group. ERT representatives will be on booth at the DIA Annual Meeting to discuss the company’s latest innovations, as well as the latest advancements within the industry.
ERT is also inviting delegates to attend a presentation from its partner, Healthcare Technology Systems (HTS) Inc., which will be held on Wednesday June 24, 3.30pm-5.00pm. The presentation entitled “Addressing Suicidality in Clinical Trials” will be chaired by John H. Greist, MD of HTS Inc and will discuss FDA safety concerns and regulatory requirements regarding suicidality assessments and the Columbia Suicide Severity Rating Scale (C-SSRS) and Columbia Classification Algorithm of Suicide Assessment (C-CASA). Delegates will be able to learn about computer-automated suicidality assessment options as well as learn about methods and techniques for follow-up with patients.
The DIA Annual Meeting is the bio-pharmaceutical industry’s largest global event, drawing over 5,000 industry professionals each year and over 450 exhibiting companies from all over the world. Additionally, DIA Annual features over 400 conference sessions including key speakers from key regulatory agencies e.g. FDA and EMEA.
ERT is a leading provider of technology and services to the biopharmaceutical and medical device industries around the world. The four key areas of ERT products and services are all enabled by the company’s innovative technology platform – EXPERT™. EXPERT™ is a robust, secure, and validated clinical-research workflow-processing system that powers centralized electronic data collection, data management, and information exchange.
For further information about ERT’s clinical trial solutions please visit Booth # 507 at DIA 45th Annual Meeting in San Diego. Alternatively, please email info[.]ERT.com, call +1 215 972 0420
About eResearchTechnology, Inc. (ERT)
Based in Philadelphia, PA ERT (ert.com) is a provider of technology and services to the global biopharmaceutical and medical device industries. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2009 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.